Clinical use of biologics in vasculitis syndromes
Biologics: Targets and Therapy, ISSN: 1177-5475, Vol: 6, Page: 371-378
2012
- 4Citations
- 47Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations4
- Citation Indexes4
- Captures47
- Readers47
- 47
Review Description
Vasculitis syndromes are relative rare conditions but can cause significant mortality and morbidity if not treated adequately. Recent advances in immunosuppressant therapy have radically changed the course of these diseases. However, the standard therapy is not always well tolerated by patients, and some cases are refractory to treatment. New therapeutic possibilities have emerged with the use of so-called "biologics," a new class of genetically engineered drugs used for inflammatory rheumatic diseases, including rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. In the present review, summarized are the most recent data on the efficacy and safety of biologics in the treatment of vasculitis syndromes that cannot be treated with standard therapy. © 2012 Paroli, publisher and licensee Dove Medical Press Ltd.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84872243572&origin=inward; http://dx.doi.org/10.2147/btt.s37537; http://www.ncbi.nlm.nih.gov/pubmed/23118526; http://www.dovepress.com/clinical-use-of-biologics-in-vasculitis-syndromes-peer-reviewed-article-BTT; https://www.dovepress.com/getfile.php?fileID=14321; https://dx.doi.org/10.2147/btt.s37537; https://www.dovepress.com/clinical-use-of-biologics-in-vasculitis-syndromes-peer-reviewed-fulltext-article-BTT
Dove Medical Press Ltd.
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know